Medtronic initiates enrollment in Enlite Sensor study for diabetes

Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite™ Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes. The study will evaluate Enlite, a glucose sensor for CGM designed to offer improved hypoglycemic detection and comfort compared to current CGM sensors. CGM provides a more complete picture of glucose control because it can reveal high and low glucose levels that periodic fingerstick testing might miss.

The first two patients in the study were enrolled at Rainier Clinical Research Center in Seattle, Wash., and at AMCR Institute in San Diego, Calif., by the sites' principal investigators (PI), Ronald Brazg, M.D., and Timothy Bailey, M.D., respectively.

"We're very excited to move forward on a path to bring to the U.S. market this latest innovation that has been designed to provide even better accuracy, comfort and ease of use," said Francine Kaufman, M.D., Chief Medical Officer and Vice President of Global Clinical Affairs for the Diabetes business of Medtronic. "The Enlite sensor is designed to provide improved hypoglycemia detection and better overall system accuracy. The study will demonstrate whether these improvements, combined with our system's ability to predict when hypoglycemic events will occur through predictive alerts, can help people with diabetes achieve better glucose control."

The landmark clinical study STAR 3 showed that patients using Medtronic's insulin pump therapy integrated with CGM achieved a reduction in mean A1C that was four times greater than patients using multiple daily injections.